

FOR IMMEDIATE RELEASE

November 29, 2013

Listed Company Name: Eisai Co., Ltd.
Representative: Haruo Naito
President & CEO
Securities Code: 4523
Stock Exchange Listings: First Section of the Tokyo
Stock Exchange
Inquiries: Sayoko Sasaki
Vice President,
Corporate Affairs
Phone +81-3-3817-5120

**Notification Regarding Execution of Business Transfer Agreement to Transfer
Business Operations at Eisai Misato Plant to Bushu Pharmaceuticals Ltd.**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") today entered into a Business Transfer Agreement with Bushu Pharmaceuticals Ltd. (Headquarters: Saitama Prefecture, President: Takayuki Kasai, "Bushu") regarding the transfer of business operations at the Misato Plant

Following this transfer, Eisai will offer its employees at the Misato Plant the option to voluntarily transfer their employment contract to Bushu. In addition, Eisai products currently manufactured at the Misato Plant excluding certain products will continue to be manufactured at the same site under the agreement.

By adapting flexibly to the rapid environmental changes in this era of great globalization in health care, Eisai aims to provide high-quality products at affordable prices to create customer joy and contribute to improving the benefits provided to patients and their families worldwide.

2. Outline of Plant to Be Transferred

- 1) Name: Misato Plant
- 2) Location: 950 Oaza-Hiroki, Misato-machi, Kodama-gun,
Saitama Prefecture, Japan
- 3) Site Area: 173,496 m²
- 4) Building Area: 58,316 m²
- 5) Employees: Approximately 210 (as of October 1, 2013)
- 6) Main Products: Tablets, capsules and parenteral formulations
- 7) Achievements: Approximately 3.8